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Hormone Therapy for Postmenopausal Women:
A Brief History of Time
Cvnthia A. Stuenkel, MD*
I. INTRODUCTION
A discussion of menopause is best framed within the perspective of the
totality of a woman's reproductive life. Similar to puberty, menopause is a
natural, physiological event experienced by all women who reach an
appropriate level of maturity with ovaries intact. Natural menopause
occurs at an average age of fifty-one years. By definition, menopause is
the final menstrual period, which marks the end of fertility and cyclical
ovarian steroid hormone production. This passage liberates women from
the inconvenience and discomfort of monthly menstrual cycles, associated
mood swings, and concerns with unintended pregnancy. While menopause
is formally defined as a single point in time, the transition to menopause
usually encompasses a number of years and offers an opportunity to
reassess lifestyle, to become more cognizant of ongoing and potential
health concerns, and to take a proactive approach to enhance future
wellbeing. Healthy women today can expect to live between one-third to
one-half of their lives after menopause.
Estrogen therapy, considered a panacea for aging when popularized
more than fifty years ago, has evolved as an accepted pharmacological
treatment for the most common symptoms of menopause: hot flashes and
vaginal dryness. It is challenging to explain why the topic of hormone
therapy has been so polarizing, so perplexing, and engenders so much
passion. Perhaps it is because for many years the practice of menopausal
medicine depended more upon "eminence-based" than "evidence-based
medicine."' In the absence of randomized clinic trial data to support
decision-making, physicians relied on data generated through less rigorous
methods and expert opinion. Advocates for the purported benefits of
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estrogen therapy (which were legion) assumed an almost evangelical zeal,
and clashes between estrogen "true-believers" and skeptics often became
heated. The initial results reported from the Women's Health Initiative
clinical trial fueled this controversy. The good news is that as the science
of menopausal health progresses, additional evidence has accumulated to
guide informed practice. This Article includes a brief overview of the
physiology of the menopause, an introduction to evidence-based medicine,
the history of research on estrogen therapy, the impact of the Women's
Health Initiative clinical trials, and the current approach to hormone
therapy in clinical practice.
II. PHYSIOLOGY OF THE MENOPAUSE
As the culmination of reproductive aging, menopause results from the
depletion of oocytes, or eggs, within the ovary.2 While aberrations of the
hypothalamic-pituitary-ovarian axis might also contribute to reproductive
senescence, accelerating atresia, or loss of ovarian follicles, is the most
plausible etiology of the menopause transition. A decrease in both ovarian
follicular number and responsiveness of the follicles to pituitary stimulating
hormones eventually leads to a decline in ovarian estrogen production.
Following wide fluctuations during the menopause transition, circulating
estradiol concentration finally reaches a level inadequate to sustain the
uterine lining, and menstruation ceases.
One of the earliest clinical signs of ovarian aging is a change in the
regularity of the menstrual cycle (see Figure 1). As the menopausal
transition progresses, women report a change in menstrual cycle length of
seven days or more. In the Late Phase of the menopause transition, as
defined by the Stages of Reproductive Aging Workshop,3 menstrual cycles
become yet more irregular and are characterized by episodes of
amenorrhea, or absent menses, for two to three consecutive cycles. At this
time, women often begin to experience the most classic symptoms of the
menopause transition, vasomotor symptoms, or hot flashes. Once a woman
has experienced a year without a menstrual cycle, she can be described as
being postmenopausal; by definition, this is a retrospective determination.
Commonly, symptoms of hot flashes and associated night sweats increase
during the years immediately following menopause. Up to eighty-five
percent of women experience hot flashes; for most, the symptoms gradually
abate after a few years, but vasomotor symptoms may persist for up to ten
years.4
2. N. AM. MENOPAUSE Soc'Y, MENOPAUSE PRACTICE: A CLINICIAN'S GUIDE, 1.1-1.5,
2.1-2.8 (4th ed. 2010).
3. Michael R. Soules et al., Executive Summary: Stages of Reproductive Aging
Workshop (STRAW) Park City Utah, July, 2001, 8 MENOPAUSE 402, 403 (2001).
4. Ellen W. Freeman et al., Duration of Menopausal Hot Flushes and Associated Risk
Factors, 117 OBSTETRICS & GYNECOLOGY 1095, 1095-1104 (2011).
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Figure 1.
Premature menopause is the term that describes loss of ovarian
function and menopause prior to the age of forty years.5 Menopause can be
induced by surgical removal of the ovaries or by ovarian damage from
chemotherapy or ionizing radiation. Primary ovarian insufficiency refers to
premature insufficiency of the ovaries due to genetic, metabolic, or
immunologic factors.
III. A LESSON IN EVIDENCE-BASED MEDICINE
Estrogen therapy has been available to relieve menopausal symptoms
since 19286 and marketed in earnest since the Food and Drug
Administration (FDA) approved Premarin in 1942. During the late 1980s
and throughout the decade of the 1990s, the belief that estrogen might
prevent diseases of aging led to widespread enthusiasm for estrogen
therapy, even for asymptomatic women well beyond menopause.
Guidelines established by the American College of Physicians in 1992
5. N. AM. MENOPAUSE Soc'v, supra note 2, at 1.3.
6. Elizabeth Barrett-Connor, An Epidemiologist Looks at Hormones and Heart Disease
in Women, 88 J. CLINICAL ENDOCRINOGY & METABOLISM 4031, 4034 (2003).
encouraged initiation of hormone therapy in virtually all postmenopausal
women without contraindications.
In 2002, however, investigators conducting the landmark National
Institute of Health (NIH) funded Women's Health Initiative (WHI) clinical
trial of combined estrogen and progestogen therapy, reported that the risks
of combination hormone therapy exceeded the benefits. The WHI findings
called the practice of prescribing hormone therapy for prevention into
question. A head-on collision between advocates of hormone therapy and
some WHI trialists followed; repercussions continue to reverberate today.
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Figure 2.
The principles of evidence-based medicine affirm why the results of
the WHI-the opposite of those anticipated-were so compelling. Prior to
the announcement of the results of the WHI in 2002, justification for the
use of hormone therapy for prevention of diseases of aging relied primarily
upon the results of observational studies, clinical outcome trials in non-
human primate models, and studies in women with surrogate outcomes
7. Deborah Grady et al., Guidelines for Counseling Postmenopausal Women about
Preventive Hormone Therapy, 117 ANNALS INTERNAL MED. 1038, 1038 (1992).
8. Writing Grp. For the Women's Health Initiative Investigators, Risks and Benefits of
Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the
Women's Health Initiative Randomized Control Trial, 288 JAMA 321, 325 (2002).
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such as lipid changes or markers of inflammation. 9 The discipline of
evidence-based medicine, initiated in 1992, requires that clinical decisions
are formally supported by data, preferably data derived from randomized
controlled trials.' 0 Within this hierarchy of data, the strongest line of
evidence for establishing the best clinical practice is the randomized
controlled trial, or meta-analysis or systemic review of multiple clinical
trials (see Figure 2). Intermediate levels of evidence include observational
studies (cohort and case-control studies). In these studies, individuals are
followed over time, but the choice of therapy, however, reflects physician
or patient preference rather than a randomization process. Observational
studies are excellent for hypothesis generation and establishing
associations, though they cannot prove causality. Basic research, including
in vitro studies, animal research, and studies of human physiology with
surrogate outcome measures all provide vital insight into possible
mechanisms of health and disease, but contribute less to informed clinical
decision making. The only lower category on the hierarchy of evidence
consists of clinical experience and expert and consensus opinions, which is
a humbling realization for most physicians.
IV. THE HISTORY OF
ESTROGEN "REPLACEMENT" THERAPY
Given the understanding of menopause as an estrogen deficiency state,
clinical efforts focused on estrogen "replacement" therapy. A number of
modes for administering ovarian steroids to menopausal women were
explored, though it was not until 1942 that Premarin, conjugated equine
estrogens in oral tablet form, was approved by the FDA and became widely
available. Premarin, as the trade name infers, originates from the urine of
pregnant mares. In 1966, Robert A. Wilson, MD, a New York
gynecologist, published Feminine Forever. The central premise of his
book reinforced the concept of menopause as a hormone deficiency
syndrome readily remedied by estrogen administration." Wilson writes:
menopause must at last be recognized as a major medical problem
in modem society. Women, after all, have the right to remain
women. They should not have to live as sexual neuters for half
their lives. The treatment and cure of menopause thus becomes a
social and moral obligation. At this point in history, medical
9. Barrett-Connor, supra note 6, at 4031-41.
10. OCEBM Levels of Evidence Working Grp., The Oxford 2011 Levels of Evidence,
OXFORD CTR FOR EVIDENCE-BASED MED., http://www.cebm.net/mod-product/design/
files/CEBM-Levels-of-Evidence-2.1.pdf (last visited Oct. 30, 2011).
11. ROBERTA. WILSON, FEMININE FOREVER (1966).
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science can no longer evade the responsibility of helping women
remain feminine for life.12
In a subsequent paper he elaborates: "by age 50 there are no ova, no
follicles, no theca, no estrogen; truly a galloping catastrophe ... with
estrogenic treatment ... breasts and genital organs will not shrivel. Such
women will be much more pleasant to live with and will not become dull
and unattractive."l 3
Funded by Wyeth Ayerst, Dr. Wilson and his publications proved to be
powerful motivators for popularizing Premarin therapy for relief of
menopause symptoms.
A. THE CORONARY DRUG PROJECT
By the mid-1960s, few clinical trials examining the effects of estrogen
therapy in postmenopausal women had been conducted. Observant
physicians, however, noted the natural difference in rates of heart disease
between men versus women and hypothesized that estrogen provided a
cardioprotective effect. As a result, the Coronary Drug Project emerged as
the first randomized clinical trial to evaluate whether Premarin reduced
cardiovascular events (specifically, myocardial infarction) in men. Men
with a history of coronary heart disease were randomly assigned to one of
several treatment arms, including conjugated equine estrogens (Premarin)
2.5 to 5.0 mg/ day (doses four to eight times larger than those prescribed to
women for symptom relief). The Premarin arm of the trial was prematurely
terminated because of an increased incidence of myocardial infarctions
(heart attacks), venous thromboembolic events (blood clots in the legs and
lungs), and fatalities compared to the placebo group.14 Investigators then
abandoned the possibility of exploring estrogen as a means to improve
heart health in men. Twenty years would pass before investigators would
design a trial to evaluate whether estrogen therapy might improve coronary
health in postmenopausal women.
B. PROTECTING THE ENDOMETRIUM WITH PROGESTOGEN THERAPY
By the 1970s, the beneficial effects of estrogen therapy for relief of
menopausal symptoms yielded more and more prescriptions. In the mid-
1970s, however, increased endometrial (uterine) cancer risk emerged in
women taking estrogen therapy. The risk increases after a year of therapy,
rises in proportion to duration of therapy, and persists for years after
12. ROBERT A. WILSON, FEMININE FOREVER 25 (1966).
13. Robert A. Wilson & Thelma A. Wilson, The Basic Philosophy of Estrogen
Maintenance. 20 J. AM. GERIATR. Soc'Y 521, 523 (1972).
14. Coronary Drug Project Research Grp., The Coronary Drug Project: Initial Findings
Leading to Modifications ofIts Research Protocol, 214 JAMA 1303, 1306 (1970); Coronary
Drug Project Research Grp., Findings Leading to Discontinuation of the 2.5-mg Day
Estrogen Group, 226 JAMA 652, 656 (1973).
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estrogen therapy is discontinued. To counteract the cancer-promoting
effects of unopposed estrogen on the uterine lining, physicians began to
prescribe a second hormone, predominantly a synthetic progestogen,
medroxyprogesterone acetate (MPA) (trade name, Provera), each month.
In an attempt to mimic the cyclical pattern of estrogen and progesterone
secretion during the natural menstrual cycle, women received twenty-eight
days of estrogen therapy along with fourteen days of concurrent
progestogen therapy starting two weeks after beginning estrogen therapy.
For a few days at the end of each month, both hormones were stopped.
During the days off, women often experienced vaginal bleeding-a
nuisance. For this reason many stopped taking hormones.
Years later, a more popular regimen evolved in an effort to reduce
bleeding during the hormone-free interval at the end of the month. Daily
administration of both estrogen and a progestogen effectively minimized
the risk of endometrial cancer, similar to that in women assigned to placebo
therapy.' 5 After months of daily combination therapy, atrophy of the
endometrium (thinning of the uterine lining) results in less (or no) bleeding,
a feature embraced by both women and their physicians.
C. THE PROMISE OF CARDIAC BENEFIT
As the 1980s progressed, a number of randomized controlled trials
highlighted additional benefits of estrogen therapy: bone mineral density
increased and cholesterol profiles improved (see Figure 3). Clinical
endpoint trials assessing the effects of hormone therapy on osteoporotic
fractures and myocardial infarctions, however, had yet to be initiated.
15. Writing Grp. for the PEPI Trial, Effects of Estrogen or Estrogen/Progesting
Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal
Estrogen/Progestin Interventions (PEPI) Trial, 273 JAMA 199, 207 (1995); Writing Grp.
For the Women's Health Initiative Investigators, supra note 8 at 206.
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Figure 3.
Findings from the Lipid Research Clinics (LRC) Program Follow-up
Study proved to be pivotal in setting the direction of future research for the
next two decades. In 1983, the LRC investigators first noted that women
who used estrogen therapy appeared to have a lower risk of mortality,16 and
specifically, fewer cardiovascular disease (CVD) deaths." Similar reports
from a number of observational studies followed, including a compelling
report suggesting that estrogen use was associated with improved survival
even in women with a personal history of coronary heart disease." As
noted by Elizabeth Barrett-Connor, MD, a prominent epidemiologist:
Despite the absence of clinical trial data, by the mid-1990s it was
almost dogma that hormone therapy would prevent coronary heart
disease in postmenopausal women. Documentation that all
postmenopausal patients had been offered estrogen was one of the
16. Trudy L. Bush et al., Estrogen Use and All-Cause Mortality: Preliminary Results
From the Lipid Research Clinics Program Follow-Up Study, 249 JAMA 903, 903-04
(1983).
17. Trudy L. Bush et al., Cardiovascular Mortality and Noncontraceptive Use of
Estrogen in Women: Results From the Lipid Research Clinics Program Follow-Up Study,
75 CIRCULATION 1102, 1102-08 (1987).
18. Jay M. Sullivan et al., Estrogen Replacement and Coronary Artery Disease: Effect on
Survival in Postmenopausal Women, 150 ARCHIVES INTERNAL MED. 2557, 2560-61 (1990).
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criteria used to evaluate the quality of medical practice. Not to
recommend estrogen therapy was thought to be unethical.' 9
Consequently, conjugated equine estrogens (Premarin) became the
most widely dispensed prescription drug in the United States.
D. THE POSTMENOPAUSAL ESTROGEN AND PROGESTOGEN
INTERVENTION TRIAL
Funded by the National Institutes of Health and initiated in 1989, the
Postmenopausal Estrogen and Progestin Interventions Trial (PEPI) set out
to evaluate the effects of oral conjugated estrogens alone or in combination
with medroxyprogesterone acetate (daily or cyclically) or micronized
progesterone (cyclically) on heart disease risk factors. The PEPI results,
published in 1995, showed that CEE alone or in combination with MPA
had beneficial or neutral effects on cholesterol levels, blood pressure,
glucose metabolism, and clotting factors.20 The most favorable lipid profile
in women on combination therapy was seen in the arm of the trial which
included micronized progesterone (MP), a formulation identical in
chemical structure to endogenous progesterone. Ironically, micronized
progesterone was not available for prescription in the U.S. at the time the
trial ended, or for some time thereafter. In an editorial addressing the PEPI
results, Dr. Bernadine Healy, MD, then Director of the NIH, commented
that, "The most important question of all, as noted by the PEPI
investigators, is whether differences in the studied surrogate markers will
translate in time to less cardiovascular disease." 21
E. THE HEART AND ESTROGEN PROGESTIN REPLACEMENT STUDY
Initiated in 1993, the Heart and Estrogen Progestin Replacement Study
(HERS) was the first clinical endpoint trial to evaluate the effect of
combination hormone therapy on heart attack and coronary heart disease
related death in women. HERS was designed to determine whether women
with a history of coronary heart disease would experience a reduction in
myocardial infarction and coronary heart disease deaths after starting
hormone therapy with daily combined conjugated estrogens (Premarin) and
medroxyprogesterone acetate (Provera). The design of the HERS trial was
in keeping with the conventional approach to evaluating pharmacologic
agents for potential cardiovascular benefit: The logical first group to study
focuses on those at highest risk for a CVD event. In a secondary
prevention trial, fewer subjects are required to show benefit (or harm) and
the duration of the trial is shorter (and less expensive) than if a healthy,
primary prevention population were studied.
19. Barrett-Connor, supra note 6, at 4033-34.
20. Writing Grp. for the PEPI Trial, supra note 15, at 202.
21. Bernadine Healy, PEPI in Perspective: Good Answers Span Pressing Questions, 273
JAMA 240, 240 (1995).
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The unanticipated results of the HERS trial were announced in 1998.
The HERS findings revealed that hormone therapy not only did not
decrease coronary heart disease in women with a history of heart attack or
coronary heart disease, but paradoxically, the women randomized to
hormone therapy experienced an increase in coronary heart disease events
in the year after therapy was started.22 These startling findings were the
opposite of the beneficial results anticipated from observational studies, but
consistent with the findings of the Coronary Drug Project in men. The
HERS trial results shocked the medical community and led to years of
study critiques and hypotheses to explain the discrepancy between HERS
results and observational studies. An editorial accompanying the HERS
publication succinctly summarized the situation: "These findings are a
sobering reminder of the limitations of observational research, the
incompleteness of current understanding of the mechanisms of vascular
disease, and the danger of extrapolation." 23
A number of additional ongoing secondary prevention trials, already
underway when the HERS results were published, went on to evaluate
clinical outcomes (heart attack and stroke); others examined changes in the
lumen of coronary arteries measured during cardiac catheterization.
Virtually all findings were consistent with HERS-no benefit of hormone
therapy to women who already had coronary heart disease. Several of the
secondary prevention trials also demonstrated early harm.24
V. THE WOMEN'S HEALTH INITIATIVE TRIAL
In 1992, the NIH embarked upon the landmark study, The Women's
Health Initiative. The purpose of the WHI was to determine the effects of
hormone therapy on chronic diseases of aging: heart attack, stroke,
osteoporotic fractures, colon cancer, breast cancer, and blood clots. The
WHI did not intend to confirm that hormone therapy was effective at
reducing symptoms of menopause such as hot flashes and vaginal dryness;
these benefits had previously been unequivocally demonstrated.
Furthermore, given that women were asked to participate in a randomized
placebo-controlled trial for eight years, those with severe hot flash
symptoms were discouraged from enrolling. Because women of all ages
had been encouraged to initiate hormone therapy for prevention of heart
disease and other health benefits, the trial intentionally recruited healthy
22. Stephen Hulley et al., Randomized Trial of Estrogen Plus Progestin for Secondary
Prevention of Coronary Heart Disease in Postmenopausal Women, 280 JAMA 605, 610-12
(1998).
23. Diana B. Petitti, Hormone Replacement Therapy and Heart Disease Prevention, 280
JAMA 650, 650 (1998).
24. CYNTHIA A. STUENKEL & ELIZABETH BARRETT-CONNOR, Lessons From Human
Trials, in CARDIOVASCULAR HEALTH AND DISEASE IN WOMEN 257, 257-77 (Pamela S.
Douglas, 2nd ed. 2002).
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women between the ages of fifty and seventy-nine years. For women with
a uterus, the investigators utilized the most commonly prescribed hormones
in the most commonly prescribed doses: oral daily conjugated equine
estrogens (Premarin), 0.625 mg, combined with oral daily
medroxyprogesterone acetate (Provera) 2.5 mg. Women without a uterus
received only conjugated estrogens.
The WHI study cost over $500 million and involved 161,808 women.
It included three clinical trials: hormone therapy (estrogen alone versus
placebo in 10,739 women with a prior hysterectomy, estrogen and
progestin versus placebo in 16,608 women with a uterus), a dietary
modification trial involving 48,835 women, and a calcium and vitamin D
supplementation trial involving 36,282 of the women already enrolled in
the hormone therapy or dietary modification trials. In addition to those
enrolled in the trials, 93,696 women participated in the Women's Health
Initiative Observational Study.
In 2002, after 5.6 years of follow-up (rather than 8.5 years as planned),
the combined therapy arm of the WHI trial was halted prematurely because
the risks of hormone therapy exceeded the benefits. For each 10,000
women in the WHI taking combined hormone therapy for one year, seven
more heart attacks, eight more strokes, eight more breast cancers, and
eighteen more blood clots occurred. Benefits of hormone therapy included
six fewer cases of colon cancer and five fewer hip fractures per 10,000
women taking hormone therapy for one year. The rate of cancer of the
uterus was similar between the treatment and placebo groups; no deaths
were attributed to hormone therapy.25
VI. IMMEDIATE IMPACT OF THE RESULTS OF
THE COMBINED THERAPY ARM OF THE WHI
The results of the WHI were released to the media prior to
dissemination through the medical community. According to media reports,
women participating in the WHI had been advised to stop taking study drug
(i.e., hormone therapy) immediately because the study had ended, and the
therapy was associated with serious risks. The message was
misinterpreted, however, to imply that all women should urgently stop
hormone therapy because of safety concerns, including recently
postmenopausal women taking hormone therapy prescribed by their
physicians for relief of vasomotor symptoms.
A. A DARK CLOUD OVER HORMONE THERAPY
The WHI results unleashed a maelstrom of uncertainty regarding the
use of hormone therapy, resulting in dissonance among the medical
community and postmenopausal women. It had been four years since the
25. Writing Grp. For the Women's Health Initiative Investigators, supra note 8 at 326.
publication of HERS, and many remained hopeful that the WHI would
confirm that hormone therapy had a preventive benefit when administered
to healthy women without baseline coronary heart disease. Following the
disappointing findings, however, the debate began in earnest as to the
validity of the WHI, the appropriateness of the women who were enrolled
in the study, the choice of hormones studied, and the generalizability of the
results and subsequent conclusions.
B. FDA ASSIGNS NEW INDICATIONS
The FDA promptly requested modification of the package labeling for
the hormone preparations studied in the WHI: conjugated equine estrogens
(Premarin) and medroxyprogesterone acetate (Provera). The FDA also
requested that all manufacturers of approved postmenopausal hormone
therapies adopt the same labeling, because in the absence of data, all
products were believed to have similar risks.
New FDA-approved indications for prescribing hormone therapy were
clearly specified: the first was treatment of moderate to severe vasomotor
symptoms associated with the menopause, with the adage that estrogen
should be prescribed at the lowest dose which relieves symptoms and for
the shortest duration for the individual women-an attempt to minimize
exposure while acknowledging that women vary in the duration and
severity of their symptoms. The second indication was treatment of
moderate to severe symptoms of vulvar and vaginal atrophy (dryness and
irritation) associated with the menopause. When prescribed solely for this
indication, topical vaginal estrogen products should be considered. The
third indication, prevention of postmenopausal osteoporosis, stipulated that
if hormone therapy was prescribed for osteoporosis prevention, women
should be at significant risk for osteoporosis and unable to take non-
estrogen bone-specific medications.26 Black box warnings were added
about serious risks and emphasized that hormones were not approved for
prevention of heart disease.
C. PRESCRIPTIONS FOR HORMONE THERAPY PLUMMET
Following the release of the WHI findings, prescriptions for hormone
therapy dropped precipitously. 27 As concern about risks of traditional
hormone therapies grew, alternatives for menopausal symptom relief were
sought,28 and a billion-dollar market for compounded hormone therapies
was born. The global medical community embarked upon a decade of
26. Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/
ucml35318.htm (last updated Jun. 22, 2010).
27. Sandra A. Tsai et al., Trends in Menopausal Hormone Therapy Use of U.S. Office-
Based Physicians 2009-2009, 18 MENOPAUSE 385, 385 (2011).
28. Heidi D. Nelson et al., Nonhormonal Therapies for Menopausal Hotflashes:
Systematic Review and Meta-analysis, 295 JAMA 2057, 2058 (2006).
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reexamining, repositioning, and rethinking the cost/benefit balance of
hormone therapy. It would take five years and a combined analysis of both
arms of the WHI trial to reassure practitioners that hormone therapy was a
safe option for symptom relief in young women, ages fifty to fifty-nine
years, who were close in time to menopause.29
VII. LESSONS LEARNED FROM THE WHI:
A. ESTROGEN ALONE-A DIFFERENT STORY
In 2004, the results of the estrogen alone trial were published, 30 and
showed that risks were markedly less than with combined therapy. From a
cardiovascular standpoint, stroke risk was increased to a similar extent, but
the risks of coronary heart disease and myocardial infarction were not. Nor
was the incidence of breast cancer increased. While deep vein thrombosis
(blood clots) occurred more frequently with estrogen therapy than placebo,
the risk of pulmonary emboli (blood clots in the lungs) was not
significantly elevated. Fractures were reduced to a similar extent as with
combined therapy; the risk of colon cancer remained unchanged from
baseline.
B. CARDIOVASCULAR EFFECTS REFLECT AGE AND YEARS SINCE
MENOPAUSE
In addition to highlighting the emerging differences between estrogen
alone versus combined hormone therapy, further analysis of the WHI
results revealed that the age of the woman and the years since her
menopause factor into the risk/benefit equation. Cardiovascular risks were
lower in younger women (ages fifty to fifty-nine years) and those women
closer in proximity (within ten years) to menopause when hormone therapy
was initiated compared with older women (seventy years and older) more
distant from menopause (twenty years or more).3  The risks of stroke
appeared to increase in women beyond age sixty years; heart attacks were
more prevalent beyond age seventy years.32 Even if one assumed that the
relative risk, or percentage increase of heart attack and stroke events was
similar across all age groups as originally reported, the baseline pre-
treatment absolute risk of cardiovascular events is so low in younger
women in their fifties, that the number of cases resulting from the adverse
effects of hormone therapy would be very small 3
29. Jacques E. Rossouw et al., Postmenopausal Hormone Therapy and Risk of
Cardiovascular Disease by Age and Years Since Menopause, 297 JAMA 1465, 1467 (2007).
30. Women's Health Initiative Steering Comm., Effects of Conjugated Equine Estrogen
in Postmenopausal Women with Hysterectomy: The Women's Health Initiative Randomized
Controlled Trial, 291 JAMA 1701, 1702 (2004).
31. Rossouw et al., supra note 29, at 1472.
32. Id. at 1473-75.
33. Deborah Grady, Management of Menopausal Symptoms, 355 NEW ENG. J. MED.
2338, 2341 (2006).
Proponents of the "Timing Hypothesis" postulate that estrogen therapy
started close to the time of menopause might prevent heart disease.3 4 In the
original report from the estrogen-alone arm of the WHI, heart attacks and
coronary heart disease death neither increased nor decreased overall in
women assigned to estrogen therapy. In women age fifty to fifty-nine
years, however, significantly fewer coronary artery revascularization
procedures (angioplasty and coronary artery bypass grafting) and
composite outcomes were reported. Coronary artery calcium (CAC), a
surrogate measure of atherosclerosis, was also reduced in women age fifty
to fifty-nine years, though effects in older women were not evaluated.36 In
a ten-year follow-up of the estrogen-alone arm of the WHI trial, women
ages fifty to fifty-nine years at enrollment experienced fewer heart attacks
and episodes of coronary heart disease and lower mortality rates than
women ages seventy to seventy-nine years.37 Two ongoing clinical trials,
the Kronos Early Estrogen Prevention Study (KEEPS)38 and the Early
versus Late Intervention Trial with Estrogen (ELITE)3 9 enrolled younger,
healthy women in close proximity to menopause. Outcomes include
surrogate measures of vascular health such as carotid intima-media
thickness and CAC. Results, anticipated in the next several years, will
either support or refute the estrogen timing hypothesis.
C. GAP TIME SINCE MENOPAUSE ALTERS BREAST EFFECTS
Concern with breast cancer risk is the other major consideration
regarding hormone therapy. Additional analysis of the results from the
combined therapy arm of the WHI which was published in 2006
demonstrated that postmenopausal women naive to hormone therapy could
anticipate a five-year safe "window" during which hormone therapy did not
appear to increase breast cancer risk.4 0  This news came as a relief to
women seeking treatment for vasomotor symptoms at the time of
menopause as well as their clinicians. More recent reports, however,
34. S. Mitchell Harman et al., Timing and Duration of Menopausal Hormone Treatment
May Affect Cardiovascular Outcomes, 124 AM. J. MED. 199, 200 (2011).
35. Judith Hsai et al., Women's Health Initiative, Conjugated Equine Estrogens and
Coronary Heart Disease, 166 ARCHIVES INTERNAL MED. 357, 357 (2006).
36. JoAnn E. Manson et al., Estrogen Therapy and Coronary-Artery Calcification, 356
NEW ENG. J. MED. 2591, 2591 (2007).
37. Andrea Z. LaCroix et al., Women's Health Initiative, Health Outcomes After
Stopping Conjugated Equine Estrogens Among Postmenopausal Women with Prior
Hysterectomy: A Randomized Controlled Trial, 205 JAMA, 1305, 1305-06 (2011).
38. V. M. Miller et al., Using Basic Science to Design a Clinical Trial: Baseline
Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study
(KEEPS), 2 J. CARDIOVASCULAR TRANSLATIONAL RES. 228, 228 (2009).
39. ELITE: Early Versus Late Intervention Trial with Estradiol, CLINICALTRIALS.GOV,
http://clinicaltrials.gov/ct2/show/NCT00114517 (last updated June 17, 2010).
40. Garnet L. Anderson et al., Prior Hormone Therapy and Breast Cancer Risk in the
Women's Health Initiative Randomized Trial of Estrogen Plus Progestin, 55 MATURITAS
103, 110 (2006).
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suggest that women who start hormone therapy in close proximity to
menopause might be at greater risk for breast cancer than women with a
longer "gap time" between menopause and initiation of therapy, which
characterized many WHI participants. 41 The findings that breast effects
differ by time since menopause underscore the complexity of the
interaction between hormone therapy and the breast.
The predominant conundrum in assessing risk/balance of hormone
therapy for postmenopausal women initiating therapy close to the time of
menopause may ultimately be weighing potential heart benefit with
potential breast risk.42 Currently, individual women and their clinicians
must balance the known benefits of symptom relief against the
uncertainties remaining at this time.
VIII. PRACTICE CHANGES IN THE WAKE OF THE WHI
The evolution of our understanding of the risks and benefits of
hormone therapy poses ongoing challenges when translating this emerging
data into clinical practice. Unquestionably, the way menopausal medicine
is practiced today has been profoundly altered by the results of the WHI.
As appropriate changes are incorporated into patient care algorithms,
however, questions still remain regarding "best practice."A3
A. RX FOR SYMPTOM RELIEF, NOT PREVENTION
Hormone therapy is currently indicated for vasomotor and vaginal
symptom relief, not prevention of chronic diseases of aging.44 This basic
tenet represents a fundamental paradigm shift from practice patterns prior
to the WHI. The FDA indications include a caveat that estrogen could be
used for prevention of osteoporosis, but only in the event that a woman had
a clearly elevated risk and that she could not tolerate bone specific agents.
Ongoing questions regarding the "timing hypothesis" and "window of
opportunity" for possible cardiac and cognitive benefit in younger women
require further study.
B. LIMIT THERAPY TO YOUNGER SYMPTOMATIC WOMEN
To minimize cardiovascular risks, initiation of hormone therapy should
primarily be limited to women ages fifty to fifty-nine years or within ten
41. Richard J. Santen et al., Postmenopausal Hormone Therapy, 95 J. CLINICAL
ENDOCRINOLOGY & METABOLISM Si, S3 (Supp. 1 Jul. 2010).
42. Hugh S. Taylor & JoAnn E. Manson, Update in Hormone Therapy Use in
Menopause, 96 J. CLINICAL ENDOCRINOLOGY & METABOLISM 255, 258, 262 (2011).
43. The N. Am. Menopause Soc'y, Estrogen and Progestogen Use in Postmenopausal
Women: 2010 Position Statement of the North American Menopause Society, 17
MENOPAUSE 242, 245-52 (2010).
44. U.S. Preventive Services Task Force, Hormone Therapy for the Prevention of
Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive
Services Task Force, 142 ANNALS INTERNAL MED. 855, 855, 858 (2005).
years of menopause. 45  Within this age group, however, the challenge
remains how to clearly identify which women will benefit the most and
suffer the least untoward effects of hormone therapy. Current expert
recommendations include careful pretreatment assessment of
contraindications, cardiovascular risks, and breast cancer risks.4 6
C. PRESCRIBE LOWER DOSES
Clinicians now routinely prescribe hormone therapy with doses half or
less of those studied in the WHI. Questions remain as to whether lower
doses really are safer. In addition to providing adequate symptom relief,
will lower doses provide the benefits of hormone therapy as demonstrated
in the WHI-reduced risk of colon cancer (with combined therapy) and
reduced osteoporotic fracture risk (with estrogen or combined therapy)?
D. PERSISTENT CHALLENGE: THE BIOIDENTICAL MARKET
Prescriptions for "bioidentical" hormones prepared by compounding
pharmacies soared in response to the uncertainties generated by the WHI
associated with traditionally prescribed hormone therapy. After a decade
of promotion, compounded hormones remain untested for safety, unproven
in clinical trials to show stated efficacy, and unregulated by the FDA for
content or consistency. Furthermore, package labeling with an explanation
of risks and benefits is not required as with FDA-approved products, so
women mistakenly assume that bioidentical hormones are safer and more
effective than "traditional" preparations. The Endocrine Society, the
American College of Obstetricians and Gynecologist, The North American
Menopause Society, and the American Medical Association continue to
advocate against the use of these untested, federally unregulated products,
but will women heed these warnings?
E. INCREASED INTEREST IN FDA-APPROVED TRANSDERMAL OPTIONS
The trend to prescribe more FDA-approved transdermal therapies
might reflect a search for "safer" options or a response to women's demand
for "bioidentical" hormones. FDA-approved transdermal estrogen
preparations (patches, gels, sprays) and some oral and vaginal preparations
are identical in chemical structure to endogenous estradiol secreted by the
ovary, so they meet the criteria for classification as "biochemically"
identical. Micronized progesterone also shares its biochemical fingerprint
with endogenous progesterone. That these preparations are truly safer than
oral preparations studied in the WHI has been suggested by the findings of
45. Rossouw et al., supra note 29, at 1469.
46. Kathryn Ann Martin & JoAnn E. Manson, Approach to the Patient with Menopausal
Symptoms, 93 J. CLINICAL ENDOCRINOLOGY & METABOLISM 4567, 4569-70, 4573 (2008); N.
Am. Menopause Soc'y, supra note 43, at 250.
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a number of observational studies, but this remains unconfirmed in
randomized controlled trials.
F. EXPLORE ALTERNATIVES FOR UTERINE PROTECTION
As the increasingly favorable effects of unopposed estrogen therapy
contrast with the increasingly detrimental effects of combined therapy,
alternatives to synthetic progestins are being explored. Some clinicians
preferentially prescribe micronized progesterone; observational studies and
the PEPI cardiovascular risk factor trial suggest that micronized
progesterone may have a better safety profile, but a trial with definitive
clinical endpoints has not been conducted. Of greater concern, some
women with a uterus elect to forego progestogen therapy completely;
unopposed estrogen therapy in a woman with a uterus increases the risk of
endometrial hyperplasia and/or carcinoma. Other approaches for
endometrial protection still under investigation include localized therapies
(vaginal progesterone gel or the levonorgestrel secreting intrauterine
device) that confine progestogen exposure to the uterus. Combination
therapy with a selective estrogen receptor modulator, bazedoxifene, is
another option under investigation. The remaining question is whether
these approaches will provide adequate long-term endometrial protection.
G. LIMIT DURATION OF THERAPY
Current practice guidelines, taking into account the rising body of
evidence provided by both randomized controlled trials and observational
studies, recommend that combined hormone therapy generally be limited in
duration to a few years after menopause, primarily with the intent to
minimize the risks of breast cancer and stroke. Because of recurrence of
bothersome symptoms, however, discontinuing hormone therapy can be
challenging. On an individual basis, some women, with careful clinical
monitoring, elect to continue combined hormone therapy for prolonged
periods. As the understanding of the risks and benefits for women who
initiate hormone therapy in close proximity to menopause continues to
evolve, more specific recommendations for safe duration of therapy will
follow. For women who have had their uterus removed, recommendations
for the duration of estrogen therapy are more liberal; stroke risk, however,
occurs at the same rate as with combined therapy. Most experts agree that
for women who experience premature menopause, in the absence of
contraindications, hormone therapy can be continued until the average age
of menopause, at which time, therapeutic options can be reassessed.
The majority of risks and benefits of hormone therapy decline within a
year or two of discontinuation. 47 Long-term follow up reveals an increased
47. Gerardo Heiss et al., Women's Health Initiative, Health Risks and Benefits 3 Years
After Stopping Randomized Treatment With Estrogen and Progestin, 299 JAMA 1036, 1042
(2008).
risk of death from non-small cell lung cancer in women who used
combined hormone therapy, specifically in past smokers and women over
the age of sixty years.48 Women who develop breast cancer while taking
combined therapy have an increase in mortality, both breast cancer deaths
as well as all-cause mortality. 4 9 An increase in ovarian cancer with either
estrogen or combined therapy is also a potential concern.
IX. THE SUMMATION
The saga of hormone therapy will continue to be written as our
knowledge regarding risks and benefits of hormone therapy continues to be
refined. In the meanwhile, younger symptomatic women close in time to
menopause can be reassured that risks of hormone therapy, while real, are
usually considered rare. Symptom relief and restoration of quality of life
may be worth the small increased risks. Ensuring that tailored therapy is
available to meet the individual needs of the individual women remains the
first priority of care. Finally, the only certainty about hormone therapy is
that our understanding, and likely practice, will continue to change.
48. Rowan T. Chlebowski et at, Women's Health Initiative, Oestrogen plus Progestin
and Lung Cancer in Postmenopausal Women (Women's Health Initiative Trial): A Post-Hoc
Analysis of a Randomised Control Trial, 374 LANCET 1243, 1246 (2009).
49. Rowan T. Chlebowski et al., Women's Health Initiative, Oestrogen Plus Progestin
and Breast Cancer Incidence and Mortality in Postmenopausal Women (Women's Health
Initiative Trial): A Post-Hoc Analysis of a Randomized Control Trial, 304 JAMA 1684,
1688 (2010).
50. Taylor & Manson, supra note 42, at 259.
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